|
|
|
|
|
|||
|
|
|||
|
|
|||
|
|||
|
Mutant Prevention Concentration for Ciprofloxacin and Levofloxacin with Pseudomonas aeruginosa |
Concentración de Prevención de Mutantes para Ciprofloxacina y Levofloxacina con Pseudomonas aeruginosa |
||
|
Ciprofloxacina, Levofloxacina, Ventana de Selección de Mutantes, Concentración de Prevención de Mutantes |
Ciprofloxacin, Levofloxacin, Mutant Selection Window, Mutant Prevention Concentration |
||
|
Hansen GT, Zhao X, Drlica K, Blondeau JM |
JM Blondeau, Department of Laboratory Medicine, University of Washington WA 98109 Seattle EE.UU. |
||
|
Bayer Corp. and the National Institutes of Health |
Los autores no manifiestan conflictos de interés |
||
|
Department of Microbiology and Immunology, University of Saskatchewan |
|||
|
ReSIIC editado en las
especialidades: |
|||
|
|
|
|
|
Sociedad Iberoamericana de Información Científica (SIIC)
|